Image: Shutterstock

We just had a string of suc­cess­ful biotech IPOs. Now what?

When CG On­col­o­gy’s $CGON IPO hit a few weeks ago, its suc­cess with in­vestors star­tled a wide swathe of biotech watch­ers who …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE